Contact

All Stories

  1. Histiocytosis development and clinical variation through the lens of genomics

    Article • The Journal of Pathology, May 2026, Wiley

    Professor Pancras C.W. Hogendoorn

  2. Publisher Correction: Academia Europaea’s guidelines for the visualization of clinical outcomes

    Article • Nature Medicine, November 2025, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  3. Academia Europaea’s guidelines for the visualization of clinical outcomes

    Article • Nature Medicine, October 2025, Springer Science + Business Media

    Professor David R Thompson, Professor Pancras C.W. Hogendoorn

  4. Vaccination Against Extracellular Vimentin Plus Doxorubicin for Canine Hemangiosarcoma

    Article • International Journal of Molecular Sciences, September 2025, MDPI AG

    Professor Pancras C.W. Hogendoorn

  5. The impact of Leiden-educated Niels Stensen (Nicolas Steno) on the advancement of medical knowledge and practices

    Article • Journal of Medical Biography, September 2025, SAGE Publications

    Professor Pancras C.W. Hogendoorn

  6. Tanzanian gut microbiota profiles linked to high but rapidly waning yellow fever antibody titers

    Article • npj Biofilms and Microbiomes, June 2025, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  7. Identification of novel small molecule inhibitors of ETS transcription factors

    Article • FEBS Letters, April 2025, Wiley

    Professor Pancras C.W. Hogendoorn

  8. Embryonic reprogramming of the tumor vasculature reveals targets for cancer therapy

    Article • Proceedings of the National Academy of Sciences, March 2025, Proceedings of the National Academy of Sciences

    Professor Pancras C.W. Hogendoorn

  9. New evidence for fibrocartilaginous dysplasia representing a variant of fibrous dysplasia

    Article • Journal of Clinical Pathology, February 2025, BMJ

    Professor Pancras C.W. Hogendoorn

  10. Recurrent ETV3::NCOA2 fusions and MAPK pathway mutations in indeterminate dendritic cell histiocytosis

    Article • Blood Advances, January 2025, American Society of Hematology

    Professor Pancras C.W. Hogendoorn

  11. Histopathologic Challenges in the Diagnostic Stage

    Article • January 2025, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  12. Recurrent CLTC::SYK fusions and CSF1R mutations in juvenile xanthogranuloma of soft tissue

    Article • Blood, December 2024, American Society of Hematology

    Professor Pancras C.W. Hogendoorn

  13. Lifestyle score is associated with cellular immune profiles in healthy Tanzanian adults

    Article • Brain Behavior & Immunity - Health, November 2024, Elsevier

    Professor Pancras C.W. Hogendoorn

  14. Immune response, Osteosarcoma and chemotherapy response

    Article • Virchows Archiv, May 2024, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  15. Demographics and additional haematologic cancers of patients with histiocytic/dendritic cell neoplasms

    Article • Histopathology, January 2024, Wiley

    Professor Pancras C.W. Hogendoorn, Arjan Diepstra

  16. Transmembrane protein 14A protects glomerular filtration barrier integrity

    Article • Physiological Reports, December 2023, Wiley

    Professor Pancras C.W. Hogendoorn

  17. Immunological factors linked to geographical variation in vaccine responses

    Article • Nature Reviews Immunology, September 2023, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  18. Brown Tumour in Chronic Kidney Disease: Revisiting an Old Disease with a New Perspective

    Article • Cancers, August 2023, MDPI AG

    Professor Pancras C.W. Hogendoorn

  19. Brown Tumour in Chronic Kidney Disease: Revisiting an Old Disease with a New Perspective

    Article • July 2023, MDPI AG

    Professor Pancras C.W. Hogendoorn

  20. The first, private and unknown small anatomical Ruijsch collection of Peter the Great

    Article • Vestnik of Saint Petersburg University Medicine, January 2023, Saint Petersburg State University

    Professor Pancras C.W. Hogendoorn

  21. Histone Deacetylase Inhibitors as a Therapeutic Strategy to Eliminate Neoplastic “Stromal” Cells from Giant Cell Tumors of Bone

    Article • Cancers, September 2022, MDPI AG

    Professor Pancras C.W. Hogendoorn

  22. Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial)

    Article • BMC Cancer, June 2022, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  23. Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): Analysis of 21 cases

    Article • Annals of Diagnostic Pathology, April 2022, Elsevier

    Professor Pancras C.W. Hogendoorn

  24. Mutations in the heparan sulfate backbone elongating enzymes EXT1 and EXT2 have no major effect on endothelial glycocalyx and the glomerular filtration barrier

    Article • Molecular Genetics and Genomics, February 2022, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  25. ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition

    Article • Blood, January 2022, American Society of Hematology

    Professor Pancras C.W. Hogendoorn

  26. Case Report: Asymptomatic COVID-19 patient with a subtle hypercoagulable state and fluctuating D-dimer level

    Article • F1000Research, November 2021, Faculty of 1000, Ltd.

    Professor Pancras C.W. Hogendoorn

  27. Cell Biology of Giant Cell Tumour of Bone: Crosstalk between m/wt Nucleosome H3.3, Telomeres and Osteoclastogenesis

    Article • Cancers, October 2021, MDPI AG

    Professor Pancras C.W. Hogendoorn

  28. NTRK fusions are extremely rare in bone tumours

    Article • Histopathology, September 2021, Wiley

    Professor Pancras C.W. Hogendoorn

  29. Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype

    Article • Blood Advances, September 2021, American Society of Hematology

    Professor Pancras C.W. Hogendoorn, Arjan Diepstra

  30. Medical instruments in Imperial Russia: from a blacksmith to a factory for medical instruments, headed by a leading surgeon N.L. Bidloo

    Article • Journal of Anatomy and Histopathology, July 2021, VSMU N.N. Burdenko

    Professor Pancras C.W. Hogendoorn

  31. Non-Hodgkin lymphoma of bone of the femur and humerus: a case report and review of the literature

    Article • Oxford Medical Case Reports, April 2021, Oxford University Press (OUP)

    Professor Pancras C.W. Hogendoorn

  32. The adapter protein Myd88 plays an important role in limiting mycobacterial growth in a zebrafish model for tuberculosis

    Article • Virchows Archiv, February 2021, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  33. Dutch cultural heritage of Fredrik Ruijsch and Herman Boerhaave in the Military Medical Academy named after S. M. Kirov

    Article • Vestnik of Saint Petersburg University Medicine, January 2021, Saint Petersburg State University

    Professor Pancras C.W. Hogendoorn

  34. Co-existence of lung carcinoma metastasis and enchondroma in the femur of a patient with Ollier disease

    Article • Virchows Archiv, October 2020, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  35. Nikolay Ivanovich Pirogov as an innovator in anatomy, surgery, and anaesthesiology. Part II

    Article • Journal of Anatomy and Histopathology, October 2020, VSMU N.N. Burdenko

    Professor Pancras C.W. Hogendoorn

  36. Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation

    Article • The Journal of Pathology Clinical Research, August 2020, Wiley

    Professor Pancras C.W. Hogendoorn

  37. Surgical Outcome and Oncological Survival of Osteofibrous Dysplasia-Like and Classic Adamantinomas

    Article • Journal of Bone and Joint Surgery, August 2020, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn, Dr Paul C Jutte

  38. Highlights of the professional activities of Nikolay Ivanovich Pirogov before and after his professoriate in Saint Petersburg (1841–1860). Part I

    Article • Journal of Anatomy and Histopathology, July 2020, VSMU N.N. Burdenko

    Professor Pancras C.W. Hogendoorn

  39. Nikolay Ivanovich Pirogov: Forerunner, co-founder and Inspector-General of the Red Cross

    Article • Vestnik of Saint Petersburg University Medicine, January 2020, Saint Petersburg State University

    Professor Pancras C.W. Hogendoorn

  40. The Dutchman Herman Boerhaave and the Russian Nikolay Ivanovich Pirogov are brilliant medical scientists, whose remembrance will be eternal

    Article • Vestnik of Saint Petersburg University Medicine, January 2020, Saint Petersburg State University

    Professor Pancras C.W. Hogendoorn

  41. Mutation-driven epigenetic alterations as a defining hallmark of central cartilaginous tumours, giant cell tumour of bone and chondroblastoma

    Article • Virchows Archiv, November 2019, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  42. The development of Russian Medicine in the Petrine era and the role of Dutch doctors in this process

    Article • Vestnik of Saint Petersburg University Medicine, November 2019, Saint Petersburg State University

    Professor Pancras C.W. Hogendoorn

  43. Nikolay Ivanovich Pirogov (1810–1881): Anatomical research to develop surgery

    Article • Clinical Anatomy, November 2019, Wiley

    Professor Pancras C.W. Hogendoorn

  44. Glomerular permeability is not affected by heparan sulfate glycosaminoglycan deficiency in zebrafish embryos

    Article • AJP Renal Physiology, November 2019, American Physiological Society

    Professor Pancras C.W. Hogendoorn

  45. Quality of Life of Patients With Osteosarcoma in the European American Osteosarcoma Study-1 (EURAMOS-1): Development and Implementation of a Questionnaire Substudy

    Article • JMIR Research Protocols, September 2019, JMIR Publications Inc.

    Professor Pancras C.W. Hogendoorn

  46. Method to measure the mismatch between target and achieved received dose intensity of chemotherapy in cancer trials: a retrospective analysis of the MRC BO06 trial in osteosarcoma

    Article • BMJ Open, May 2019, BMJ

    Professor Pancras C.W. Hogendoorn

  47. Adjuvant Zoledronic Acid in High-Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial

    Article • The Oncologist, April 2019, Oxford University Press (OUP)

    Professor Pancras C.W. Hogendoorn, Dr Paul C Jutte

  48. Non‐ossifying fibroma: A RAS‐MAPK driven benign bone neoplasm

    Article • The Journal of Pathology, March 2019, Wiley

    Professor Pancras C.W. Hogendoorn

  49. A novel method to address the association between received dose intensity and survival outcome: benefits of approaching treatment intensification at a more individualised level in a trial of the European Osteosarcoma Intergroup

    Article • Cancer Chemotherapy and Pharmacology, March 2019, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  50. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

    Article • European Journal of Cancer, March 2019, Elsevier

    Professor Pancras C.W. Hogendoorn

  51. New indicators and indexes for benchmarking university–industry–government innovation in medical and life science clusters: results from the European FP7 Regions of Knowledge HealthTIES project

    Article • Health Research Policy and Systems, January 2019, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  52. Women in healthcare in Imperial Russia: The contribution of the surgeon Nikolay I Pirogov

    Article • Journal of Medical Biography, January 2019, SAGE Publications

    Professor Pancras C.W. Hogendoorn

  53. Conjunctival Leiomyosarcoma, a Rare Neoplasm Always Originating at the Limbus? Report of a New Case and Review of 11 Published Cases

    Article • Ocular Oncology and Pathology, January 2019, Karger Publishers

    Professor Pancras C.W. Hogendoorn

  54. Pleomorphic Sarcomas

    Article • January 2019, Elsevier

    Professor Pancras C.W. Hogendoorn

  55. Markov moment for the agglomerative method of clustering in Euclidean space

    Article • Vestnik of Saint Petersburg University Applied Mathematics Computer Science Control Processes, January 2019, Saint Petersburg State University

    Professor Pancras C.W. Hogendoorn

  56. M-CSF and IL-34 expression as indicators for growth in sporadic vestibular schwannoma

    Article • Virchows Archiv, December 2018, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  57. Increased dynamin expression precedes proteinuria in glomerular disease

    Article • The Journal of Pathology, November 2018, Wiley

    Professor Pancras C.W. Hogendoorn

  58. Introducing fluorescence guided surgery into orthopedic oncology: A systematic review of candidate protein targets for Ewing sarcoma

    Article • Journal of Surgical Oncology, September 2018, Wiley

    Dr. CFM Sier, Professor Pancras C.W. Hogendoorn

  59. Molecular genetics of Ewing sarcoma, model systems and finding novel (immuno-) therapeutic targets

    Article • July 2018, OAE Publishing

    Professor Pancras C.W. Hogendoorn

  60. Bioorthogonally Applicable Fluorescence Deactivation Strategy for Receptor Kinetics Study and Theranostic Pretargeting Approaches

    Article • ChemBioChem, July 2018, Wiley

    Professor Pancras C.W. Hogendoorn

  61. The incidence, mutational status, risk classification and referral pattern of gastro-intestinal stromal tumours in the Netherlands: a nationwide pathology registry (PALGA) study

    Article • Virchows Archiv, January 2018, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  62. Cancer of Bones and Joints

    Article • January 2018, Elsevier

    Professor Pancras C.W. Hogendoorn

  63. BCRP expression in schwannoma, plexiform neurofibroma and MPNST

    Article • Oncotarget, September 2017, Impact Journals, LLC

    Professor Pancras C.W. Hogendoorn

  64. Hematopoietic Tumors Primarily Presenting in Bone

    Article • Surgical Pathology Clinics, September 2017, Elsevier

    Professor Pancras C.W. Hogendoorn

  65. Fluorescent CXCR4 targeting peptide as alternative for antibody staining in Ewing sarcoma

    Article • BMC Cancer, May 2017, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  66. Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal...

    Article • Journal of Clinical Oncology, May 2017, American Society of Clinical Oncology (ASCO)

    Professor Pancras C.W. Hogendoorn

  67. Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study

    Article • Acta Oncologica, April 2017, Taylor & Francis

    Professor Pancras C.W. Hogendoorn

  68. ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma. A critical review

    Article • Critical Reviews in Oncology/Hematology, February 2017, Elsevier

    Professor Pancras C.W. Hogendoorn

  69. High prevalence of autoimmune disease in the rare inflammatory bone disorder sternocostoclavicular hyperostosis: survey of a Dutch cohort

    Article • Orphanet Journal of Rare Diseases, January 2017, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  70. MRI appearances of atypical cartilaginous tumour/grade I chondrosarcoma after treatment by curettage, phenolisation and allografting

    Article • The Bone & Joint Journal, December 2016, Bone & Joint

    Professor Pancras C.W. Hogendoorn

  71. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

    Article • The Lancet Oncology, October 2016, Elsevier

    Dr. Heike Elisabeth Daldrup-Link, Professor Pancras C.W. Hogendoorn

  72. Erratum: Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival

    Article • Modern Pathology, September 2016, Elsevier

    Professor Pancras C.W. Hogendoorn

  73. Expression of CCL21 in Ewing sarcoma shows an inverse correlation with metastases and is a candidate target for immunotherapy

    Article • Medical Oncology, July 2016, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  74. Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival

    Article • Modern Pathology, June 2016, Elsevier

    Professor Pancras C.W. Hogendoorn

  75. CXCR4 signaling is controlled by immobilization at the plasma membrane

    Article • Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, April 2016, Elsevier

    Professor Pancras C.W. Hogendoorn

  76. Nikolay Ivanovich Pirogov (1810–1881): A pioneering Russian surgeon and medical scientist

    Article • Journal of Medical Biography, March 2016, SAGE Publications

    Professor Pancras C.W. Hogendoorn

  77. Molecular Genetics of Multiple Osteochondromas

    Article • January 2016, Wiley

    Professor Pancras C.W. Hogendoorn

  78. Automation of Technology for Cancer Research

    Article • January 2016, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  79. Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway

    Article • European Journal of Cancer, January 2016, Elsevier

    Professor Pancras C.W. Hogendoorn

  80. MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation

    Article • Genes & Cancer, December 2015, Impact Journals, LLC

    Professor Pancras C.W. Hogendoorn

  81. A translocation t(6;14) in two cases of leiomyosarcoma: Molecular cytogenetic and array-based comparative genomic hybridization characterization

    Article • Cancer Genetics, November 2015, Elsevier

    Professor Pancras C.W. Hogendoorn

  82. CXCL14, CXCR7 expression and CXCR4 splice variant ratio associate with survival and metastases in Ewing sarcoma patients

    Article • European Journal of Cancer, November 2015, Elsevier

    Professor Pancras C.W. Hogendoorn

  83. Prognosis of Primary and Recurrent Chondrosarcoma of the Rib

    Article • Annals of Surgical Oncology, October 2015, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  84. Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors

    Article • Oncotarget, October 2015, Impact Journals, LLC

    Professor Pancras C.W. Hogendoorn

  85. Novel splice variants of CXCR4 identified by transcriptome sequencing

    Article • Biochemical and Biophysical Research Communications, October 2015, Elsevier

    Professor Pancras C.W. Hogendoorn

  86. Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin

    Article • Oncotarget, September 2015, Impact Journals, LLC

    Professor Pancras C.W. Hogendoorn

  87. Tumor Biology of Vestibular Schwannoma

    Article • Otology & Neurotology, August 2015, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  88. Abstract 3780: Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in osteosarcoma cells

    Article • Cancer Research, August 2015, American Association for Cancer Research (AACR)

    Professor Pancras C.W. Hogendoorn

  89. Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic Landscapes

    Article • International Journal of Molecular Sciences, July 2015, MDPI AG

    Professor Pancras C.W. Hogendoorn

  90. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Resp...

    Article • Journal of Clinical Oncology, July 2015, American Society of Clinical Oncology (ASCO)

    Mr Matthew R Sydes, Professor Pancras C.W. Hogendoorn

  91. Mesenchymal stromal cells of osteosarcoma patients do not show evidence of neoplastic changes during long-term culture

    Article • Clinical Sarcoma Research, June 2015, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  92. Chemotherapy in osteosarcoma

    Article • The Journal of Pathology, March 2015, Wiley

    Professor Pancras C.W. Hogendoorn

  93. Periosteal chondrosarcoma: a histopathological and molecular analysis of a rare chondrosarcoma subtype

    Article • Histopathology, March 2015, Wiley

    Professor Pancras C.W. Hogendoorn

  94. Neoadjuvant denosumab for extensive giant cell tumor in os ischium —a case report

    Article • Acta Orthopaedica, February 2015, Acta Dermato-Venereologica

    Professor Pancras C.W. Hogendoorn

  95. Epidemiology of primary bone tumors and economical aspects of bone metastases

    Article • January 2015, Elsevier

    Professor Pancras C.W. Hogendoorn

  96. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials

    Article • Annals of Oncology, December 2014, Elsevier

    Professor Pancras C.W. Hogendoorn

  97. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment

    Article • Annals of Oncology, November 2014, Oxford University Press (OUP)

    Mr Matthew R Sydes, Professor Pancras C.W. Hogendoorn

  98. Nikolay Ivanovich Pirogov: a surgeon's contribution to military and civilian anaesthesia

    Article • Anaesthesia, November 2014, Wiley

    Professor Pancras C.W. Hogendoorn

  99. De novodiscovery of phenotypic intratumour heterogeneity using imaging mass spectrometry

    Article • The Journal of Pathology, November 2014, Wiley

    Professor Pancras C.W. Hogendoorn

  100. In Reply

    Article • The Oncologist, October 2014, Oxford University Press (OUP)

    Professor Pancras C.W. Hogendoorn

  101. Gene expression profiling of giant cell tumor of bone reveals downregulation of extracellular matrix components decorin and lumican associated with lung metastasis

    Article • Virchows Archiv, October 2014, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  102. Quantification of the Heterogeneity of Prognostic Cellular Biomarkers in Ewing Sarcoma Using Automated Image and Random Survival Forest Analysis

    Article • PLOS One, September 2014, PLOS

    Professor Pancras C.W. Hogendoorn

  103. 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk

    Article • Journal of the American College of Cardiology, July 2014, Elsevier

    Professor Pancras C.W. Hogendoorn

  104. Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53

    Article • The Journal of Pathology, June 2014, Wiley

    Professor Pancras C.W. Hogendoorn

  105. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance

    Article • Cancer, May 2014, Wiley

    Professor Pancras C.W. Hogendoorn

  106. Molecular genetics of chondroid tumours

    Article • Diagnostic Histopathology, May 2014, Elsevier

    Professor Pancras C.W. Hogendoorn

  107. The Clinical Approach Toward Giant Cell Tumor of Bone

    Article • The Oncologist, April 2014, Alphamed Press

    Lizz van der Heijden, Professor Pancras C.W. Hogendoorn

  108. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

    Article • The Lancet Oncology, April 2014, Elsevier

    Professor Pancras C.W. Hogendoorn

  109. GRM1 is upregulated through gene fusion and promoter swapping in chondromyxoid fibroma

    Article • Nature Genetics, March 2014, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  110. Possible effects of EXT2 on mesenchymal differentiation - lessons from the zebrafish

    Article • Orphanet Journal of Rare Diseases, March 2014, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  111. Primary intraosseous manifestation of Rosai-Dorfman disease: 2 cases and review of literature

    Article • Journal of the Belgian Society of Radiology, March 2014, Ubiquity Press, Ltd.

    Professor Pancras C.W. Hogendoorn

  112. Kinome and mRNA expression profiling of high-grade osteosarcoma cell lines implies Akt signaling as possible target for therapy

    Article • BMC Medical Genomics, January 2014, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  113. Transactivating mutation of theMYOD1gene is a frequent event in adult spindle cell rhabdomyosarcoma

    Article • The Journal of Pathology, January 2014, Wiley

    Professor Pancras C.W. Hogendoorn

  114. Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogen...

    Article • European Journal of Cancer, January 2014, Elsevier

    Professor Pancras C.W. Hogendoorn

  115. Zebrafish as a Model for Human Osteosarcoma

    Article • January 2014, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  116. The Molecular Mechanisms of Gradient Sensing by CXCR4

    Article • Biophysical Journal, January 2014, Elsevier

    Professor Pancras C.W. Hogendoorn

  117. The density of CD8+ T-cell infiltration and expression of BCL2 predicts outcome of primary diffuse large B-cell lymphoma of bone

    Article • Virchows Archiv, December 2013, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  118. Recurrent Chromosome 22 Deletions in Osteoblastoma Affect Inhibitors of the Wnt/Beta-Catenin Signaling Pathway

    Article • PLOS One, November 2013, PLOS

    Professor Pancras C.W. Hogendoorn

  119. Frequent truncating mutations of STAG2 in bladder cancer

    Article • Nature Genetics, October 2013, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  120. Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis—an EORTC STBSG and ROG study (EORTC 62991–22998)

    Article • Annals of Oncology, October 2013, Elsevier

    Professor Pancras C.W. Hogendoorn

  121. Mesenchymal stem cell transformation and sarcoma genesis

    Article • Clinical Sarcoma Research, July 2013, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  122. CD99-positive undifferentiated round cell sarcoma diagnosed on fine needle aspiration cytology, later found to harbour aCIC-DUX4translocation: a recently described entity

    Article • Cytopathology, July 2013, Wiley

    Professor Pancras C.W. Hogendoorn

  123. IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma

    Article • BMC Cancer, May 2013, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  124. FXR regulates CETP

    Article • Journal of Lipid Research, April 2013, American Society for Biochemistry & Molecular Biology (ASBMB)

    thierry claudel, Professor Pancras C.W. Hogendoorn

  125. Screening for Potential Targets for Therapy in Mesenchymal, Clear Cell, and Dedifferentiated Chondrosarcoma Reveals Bcl-2 Family Members and TGFβ as Potential Targets

    Article • American Journal Of Pathology, April 2013, Elsevier

    Professor Pancras C.W. Hogendoorn

  126. Imaging Mass Spectrometry-based Molecular Histology Differentiates Microscopically Identical and Heterogeneous Tumors

    Article • Journal of Proteome Research, March 2013, American Chemical Society (ACS)

    Professor Pancras C.W. Hogendoorn

  127. Genome-wide analyses on high-grade osteosarcoma: Making sense of a genomically most unstable tumor

    Article • International Journal of Cancer, March 2013, Wiley

    Professor Pancras C.W. Hogendoorn

  128. Tumor-Associated Macrophages Are Related to Volumetric Growth of Vestibular Schwannomas

    Article • Otology & Neurotology, February 2013, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  129. Nuclear factor-κB activation in primary lymphoma of bone

    Article • Virchows Archiv, January 2013, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  130. MicroRNAs at the human 14q32 locus have prognostic significance in osteosarcoma

    Article • Orphanet Journal of Rare Diseases, January 2013, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  131. Inactivation of Patched1 in Mice Leads to Development of Gastrointestinal Stromal-Like Tumors That Express Pdgfrα but Not Kit

    Article • Gastroenterology, January 2013, Elsevier

    Professor Pancras C.W. Hogendoorn

  132. Pleomorphic Sarcomas

    Article • January 2013, Elsevier

    Professor Pancras C.W. Hogendoorn

  133. Understanding the Molecular Mechanism of Gradient Sensing

    Article • Biophysical Journal, January 2013, Elsevier

    Professor Pancras C.W. Hogendoorn

  134. NFATC2 (nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2)

    Article • Atlas of Genetics and Cytogenetics in Oncology and Haematology, January 2013, INIST-CNRS

    Professor Pancras C.W. Hogendoorn

  135. Mutations affecting BRAF, EGFR, PIK3CA, and KRAS are not associated with sporadic vestibular schwannomas

    Article • Virchows Archiv, December 2012, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  136. Osteosarcoma of the hands and feet: a distinct clinico-pathological subgroup

    Article • Virchows Archiv, December 2012, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  137. The activities of Smad and Gli mediated signalling pathways in high-grade conventional osteosarcoma

    Article • European Journal of Cancer, December 2012, Elsevier

    Professor Pancras C.W. Hogendoorn

  138. Integrative Analysis Reveals Relationships of Genetic and Epigenetic Alterations in Osteosarcoma

    Article • PLOS One, November 2012, PLOS

    Professor Pancras C.W. Hogendoorn

  139. ‘The chicken or the egg?’ dilemma strikes back for the controlling mechanism in chordoma#

    Article • The Journal of Pathology, October 2012, Wiley

    Professor Pancras C.W. Hogendoorn

  140. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial

    Article • The Lancet Oncology, October 2012, Elsevier

    Professor Pancras C.W. Hogendoorn

  141. Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Article • Annals of Oncology, October 2012, Elsevier

    Professor Pancras C.W. Hogendoorn

  142. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Article • Annals of Oncology, October 2012, Elsevier

    Professor Pancras C.W. Hogendoorn

  143. High frequency of MYC gene amplification is a common feature of radiation‐induced sarcomas. Further results from EORTC STBSG TL 01/01

    Article • Genes Chromosomes and Cancer, September 2012, Wiley

    Professor Pancras C.W. Hogendoorn

  144. Malignant fibrous histiocytoma and fibrosarcoma of bone: a re-assessment in the light of currently employed morphological, immunohistochemical and molecular approaches

    Article • Virchows Archiv, September 2012, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  145. Interobserver reliability in the histopathological diagnosis of cartilaginous tumors in patients with multiple osteochondromas

    Article • Modern Pathology, September 2012, Elsevier

    Professor Pancras C.W. Hogendoorn

  146. Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone

    Article • BMC Cancer, August 2012, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  147. Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer

    Article • Cancer Research, August 2012, American Association for Cancer Research (AACR)

    Professor Pancras C.W. Hogendoorn

  148. Imaging mass spectrometry statistical analysis

    Article • Journal of Proteomics, August 2012, Elsevier

    Professor Pancras C.W. Hogendoorn

  149. A multidisciplinary approach to giant cell tumors of tendon sheath and synovium—A critical appraisal of literature and treatment proposal

    Article • Journal of Surgical Oncology, July 2012, Wiley

    Lizz van der Heijden, Professor Pancras C.W. Hogendoorn

  150. Expression of ERG, an Ets family transcription factor, identifies ERG-rearranged Ewing sarcoma

    Article • Modern Pathology, July 2012, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  151. Low-Grade Chondrosarcoma of Long Bones Treated with Intralesional Curettage Followed by Application of Phenol, Ethanol, and Bone-Grafting

    Article • Journal of Bone and Joint Surgery, July 2012, The Journal of Bone and Joint Surgery, Inc.

    Professor Pancras C.W. Hogendoorn

  152. The management of diffuse-type giant cell tumour (pigmented villonodular synovitis) and giant cell tumour of tendon sheath (nodular tenosynovitis)

    Article • The Bone & Joint Journal, June 2012, Bone & Joint

    Lizz van der Heijden, Professor Pancras C.W. Hogendoorn

  153. Intratumoral hemorrhage, vessel density, and the inflammatory reaction contribute to volume increase of sporadic vestibular schwannomas

    Article • Virchows Archiv, May 2012, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  154. Molecular pathology and its diagnostic use in bone tumors

    Article • Cancer Genetics, May 2012, Elsevier

    Professor Pancras C.W. Hogendoorn

  155. Smooth muscle actin expression in primary bone tumours

    Article • Virchows Archiv, April 2012, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  156. Abstract 5128: Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data

    Article • Cancer Research, April 2012, American Association for Cancer Research (AACR)

    Professor Pancras C.W. Hogendoorn

  157. Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data

    Article • Genes Chromosomes and Cancer, March 2012, Wiley

    Professor Pancras C.W. Hogendoorn

  158. Phenol levels during intralesional curettage and local adjuvant treatment of benign and low-grade malignant bone tumours

    Article • Clinical Sarcoma Research, March 2012, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  159. An osteosarcoma zebrafish model implicates Mmp‐19 and Ets‐1 as well as reduced host immune response in angiogenesis and migration

    Article • The Journal of Pathology, March 2012, Wiley

    Professor Pancras C.W. Hogendoorn

  160. Intact interferon signaling in peripheral blood leukocytes of high-grade osteosarcoma patients

    Article • Medical Oncology, March 2012, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  161. Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup

    Article • European Journal of Cancer, March 2012, Elsevier

    Mr Matthew R Sydes, Professor Pancras C.W. Hogendoorn

  162. The clinical use of biomarkers as prognostic factors in Ewing sarcoma

    Article • Clinical Sarcoma Research, February 2012, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  163. The clinical impact of molecular techniques on diagnostic pathology of soft tissue and bone tumours

    Article • Diagnostic Histopathology, February 2012, Elsevier

    Professor Pancras C.W. Hogendoorn

  164. Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma

    Article • Clinical Cancer Research, January 2012, American Association for Cancer Research (AACR)

    Professor Pancras C.W. Hogendoorn

  165. HSPG-Deficient Zebrafish Uncovers Dental Aspect of Multiple Osteochondromas

    Article • PLOS One, January 2012, PLOS

    Professor Pancras C.W. Hogendoorn

  166. The CXCR4-CXCL12 axis in Ewing sarcoma: promotion of tumor growth rather than metastatic disease

    Article • Clinical Sarcoma Research, January 2012, Springer Science + Business Media

    Dr Helen J Knowles, Professor Pancras C.W. Hogendoorn

  167. Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis

    Article • Clinical Sarcoma Research, January 2012, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  168. Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment

    Article • Clinical Sarcoma Research, January 2012, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  169. The First European Interdisciplinary Ewing Sarcoma Research Summit

    Article • Frontiers in Oncology, January 2012, Frontiers

    Professor Pancras C.W. Hogendoorn

  170. Paratesticular desmoplastic small round cell tumor: an unusual tumor with an unusual fusion, cytogenetic and molecular genetic analysis combining RT-PCR and COBRA-FISH

    Article • Clinical Sarcoma Research, January 2012, Springer Science + Business Media

    PhD Hans J Baelde, Professor Pancras C.W. Hogendoorn

  171. Analysis of stromal cells in osteofibrous dysplasia and adamantinoma of long bones

    Article • Modern Pathology, January 2012, Elsevier

    Professor Pancras C.W. Hogendoorn

  172. Automated microinjection of cell-polymer suspensions in 3D ECM scaffolds for high-throughput quantitative cancer invasion screens

    Article • Biomaterials, January 2012, Elsevier

    Professor Pancras C.W. Hogendoorn

  173. Osteosarcoma Models: From Cell Lines to Zebrafish

    Article • Sarcoma, January 2012, Hindawi Publishing Corporation

    Professor Pancras C.W. Hogendoorn

  174. Molecular Mechanisms of Gradient Sensing in Ewing's Sarcoma Cells

    Article • Biophysical Journal, January 2012, Elsevier

    Professor Pancras C.W. Hogendoorn

  175. Incidence, Predictive Factors, and Prognosis of Chondrosarcoma in Patients with Ollier Disease and Maffucci Syndrome: An International Multicenter Study of 161 Patients

    Article • The Oncologist, December 2011, Oxford University Press (OUP)

    Professor Pancras C.W. Hogendoorn, Dr Paul C Jutte

  176. Peripheral chondrosarcoma progression is associated with increased type X collagen and vascularisation

    Article • Virchows Archiv, November 2011, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  177. Epiphyseal growth plate and secondary peripheral chondrosarcoma: the neighbours matter

    Article • The Journal of Pathology, November 2011, Wiley

    Professor Pancras C.W. Hogendoorn

  178. Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?

    Article • European Journal of Cancer, November 2011, Elsevier

    Professor Pancras C.W. Hogendoorn

  179. Identification of a novel, recurrent HEY1‐NCOA2 fusion in mesenchymal chondrosarcoma based on a genome‐wide screen of exon‐level expression data

    Article • Genes Chromosomes and Cancer, October 2011, Wiley

    Professor Pancras C.W. Hogendoorn

  180. Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials

    Article • Annals of Oncology, October 2011, Oxford University Press (OUP)

    Mr Matthew R Sydes, Professor Pancras C.W. Hogendoorn

  181. Reclassification and subtyping of so-called malignant fibrous histiocytoma of bone: comparison with cytogenetic features

    Article • Clinical Sarcoma Research, October 2011, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  182. Multiple Statistical Analysis Techniques Corroborate Intratumor Heterogeneity in Imaging Mass Spectrometry Datasets of Myxofibrosarcoma

    Article • PLOS One, September 2011, PLOS

    Professor Pancras C.W. Hogendoorn

  183. mRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts

    Article • BMC Medical Genomics, September 2011, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  184. Workshop Report on the European Bone Sarcoma Networking Meeting: Integration of Clinical Trials with Tumor Biology

    Article • Journal of Adolescent and Young Adult Oncology, September 2011, Mary Ann Liebert Inc

    Professor Pancras C.W. Hogendoorn

  185. 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma

    Article • Oncogene, August 2011, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  186. Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT

    Article • Oncogene, August 2011, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  187. Functional characterization of osteosarcoma cell lines provides representative models to study the human disease

    Article • Laboratory Investigation, August 2011, Elsevier

    Professor Pancras C.W. Hogendoorn

  188. Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo

    Article • Clinical Sarcoma Research, July 2011, Springer Science + Business Media

    Professor Marcel Karperien, Professor Pancras C.W. Hogendoorn

  189. A ΔRaf1–ER‐inducible oncogenic zebrafish liver cell model identifies hepatocellular carcinoma signatures

    Article • The Journal of Pathology, July 2011, Wiley

    Professor Pancras C.W. Hogendoorn

  190. Breakpoint characterization of large deletions in EXT1 or EXT2 in 10 Multiple Osteochondromas families

    Article • BMC Medical Genetics, June 2011, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  191. A short-term in vivo model for giant cell tumor of bone

    Article • BMC Cancer, June 2011, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  192. Exploratory analysis of prognostic factors for patients (pts) with advanced soft tissue sarcoma (ASTS) receiving combination chemotherapy: A joined study of the EORTC Soft Tissue and Bone Sarcoma Group and the French Sarcoma Group.

    Article • Journal of Clinical Oncology, May 2011, American Society of Clinical Oncology (ASCO)

    Professor Pancras C.W. Hogendoorn

  193. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours

    Article • The Journal of Pathology, May 2011, Wiley

    Professor Pancras C.W. Hogendoorn

  194. IGF1R Signaling in Ewing Sarcoma Is Shaped by Clathrin-/Caveolin-Dependent Endocytosis

    Article • PLOS One, May 2011, PLOS

    Professor Pancras C.W. Hogendoorn

  195. Maffucci syndrome: A genome‐wide analysis using high resolution single nucleotide polymorphism and expression arrays on four cases

    Article • Genes Chromosomes and Cancer, May 2011, Wiley

    Professor Pancras C.W. Hogendoorn

  196. The immunophenotype of osteoclasts and macrophage polykaryons

    Article • Journal of Clinical Pathology, May 2011, BMJ

    Professor Pancras C.W. Hogendoorn

  197. Growth plate regulation and osteochondroma formation: insights from tracing proteoglycans in zebrafish models and human cartilage

    Article • The Journal of Pathology, April 2011, Wiley

    Professor Pancras C.W. Hogendoorn

  198. Podoplanin expression in adamantinoma of long bones and osteofibrous dysplasia

    Article • Virchows Archiv, April 2011, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  199. Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents

    Article • Clinical Cancer Research, April 2011, American Association for Cancer Research (AACR)

    Professor Pancras C.W. Hogendoorn

  200. Survival after recurrent osteosarcoma: Data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials

    Article • European Journal of Cancer, April 2011, Elsevier

    Mr Matthew R Sydes, Professor Pancras C.W. Hogendoorn

  201. Abstract 4295: High-throughput screening of osteosarcoma progression: A zebrafish model

    Article • Cancer Research, April 2011, American Association for Cancer Research (AACR)

    Professor Pancras C.W. Hogendoorn

  202. Concise Review: Mesenchymal Tumors: When Stem Cells Go Mad

    Article • Stem Cells, March 2011, Oxford University Press (OUP)

    Professor Pancras C.W. Hogendoorn

  203. Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells

    Article • Medical Oncology, January 2011, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  204. Genome-wide analysis of Ollier disease: Is it all in the genes?

    Article • Orphanet Journal of Rare Diseases, January 2011, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  205. Cartilage ultrastructure in proteoglycan‐deficient zebrafish mutants brings to light new candidate genes for human skeletal disorders

    Article • The Journal of Pathology, January 2011, Wiley

    Professor Pancras C.W. Hogendoorn

  206. Opening the archives for state of the art tumour genetic research: sample processing for array-CGH using decalcified, formalin-fixed, paraffin-embedded tissue-derived DNA samples

    Article • BMC Research Notes, January 2011, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  207. Distinct histological features characterize primary angiosarcoma of bone

    Article • Histopathology, January 2011, Wiley

    Professor Pancras C.W. Hogendoorn

  208. First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC Soft Tissue and Bone Sarcoma Group study

    Article • Annals of Oncology, January 2011, Elsevier

    Professor Pancras C.W. Hogendoorn

  209. Late sarcoma development after curettage and bone grafting of benign bone tumors

    Article • European Journal of Radiology, January 2011, Elsevier

    Professor Pancras C.W. Hogendoorn

  210. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8+ T-lymphocyte infiltration and affect tumour progression

    Article • The Journal of Pathology, December 2010, Wiley

    Professor Pancras C.W. Hogendoorn

  211. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target

    Article • The Journal of Pathology, December 2010, Wiley

    Professor Pancras C.W. Hogendoorn

  212. Tiling resolution array-CGH shows that somatic mosaic deletion of the EXT gene is causative in EXT gene mutation negative multiple osteochondromas patients

    Article • Human Mutation, December 2010, Hindawi Publishing Corporation

    Professor Pancras C.W. Hogendoorn

  213. Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional‐based study

    Article • The Journal of Pathology, November 2010, Wiley

    Professor Pancras C.W. Hogendoorn

  214. Cancer biology and genomics: translating discoveries, transforming pathology

    Article • The Journal of Pathology, November 2010, Wiley

    Professor Pancras C.W. Hogendoorn

  215. A nation‐wide study comparing sporadic and familial adenomatous polyposis‐related desmoid‐type fibromatoses

    Article • International Journal of Cancer, November 2010, Wiley

    Professor Pancras C.W. Hogendoorn

  216. Array-based comparative genomic hybridisation analysis reveals recurrent chromosomal alterations in primary diffuse large B cell lymphoma of bone

    Article • Journal of Clinical Pathology, October 2010, BMJ

    Professor Pancras C.W. Hogendoorn

  217. No Haploinsufficiency but Loss of Heterozygosity for EXT in Multiple Osteochondromas

    Article • American Journal Of Pathology, October 2010, Elsevier

    Professor Marcel Karperien, Professor Pancras C.W. Hogendoorn

  218. Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and Casein Kinase II inhibition as a potential treatment option

    Article • Molecular Cancer, September 2010, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  219. Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma

    Article • Oncogene, September 2010, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  220. Coactivated Platelet-Derived Growth Factor Receptor α and Epidermal Growth Factor Receptor Are Potential Therapeutic Targets in Intimal Sarcoma

    Article • Cancer Research, September 2010, American Association for Cancer Research (AACR)

    Professor Pancras C.W. Hogendoorn

  221. Imaging mass spectrometry of myxoid sarcomas identifies proteins and lipids specific to tumour type and grade, and reveals biochemical intratumour heterogeneity

    Article • The Journal of Pathology, September 2010, Wiley

    Professor Pancras C.W. Hogendoorn

  222. Heterogeneous and Complex Rearrangements of Chromosome Arm 6q in Chondromyxoid Fibroma

    Article • American Journal Of Pathology, September 2010, Elsevier

    Professor Pancras C.W. Hogendoorn

  223. Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone

    Article • BMC Cancer, August 2010, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  224. Small deletions but not methylation underlie CDKN2A/p16 loss of expression in conventional osteosarcoma

    Article • Genes Chromosomes and Cancer, August 2010, Wiley

    Professor Pancras C.W. Hogendoorn

  225. Hierarchical clustering of flow cytometry data for the study of conventional central chondrosarcoma

    Article • Journal of Cellular Physiology, August 2010, Wiley

    Professor Pancras C.W. Hogendoorn

  226. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours

    Article • Histopathology, August 2010, Wiley

    Professor Pancras C.W. Hogendoorn

  227. Primary cilia organization reflects polarity in the growth plate and implies loss of polarity and mosaicism in osteochondroma

    Article • Laboratory Investigation, July 2010, Elsevier

    Professor Pancras C.W. Hogendoorn

  228. Cartilage tumours and bone development: molecular pathology and possible therapeutic targets

    Article • Nature Reviews Drug Discovery, June 2010, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  229. A Reappraisal of Hemangiopericytoma of Bone; Analysis of Cases Reclassified as Synovial Sarcoma and Solitary Fibrous Tumor of Bone

    Article • The American Journal of Surgical Pathology, June 2010, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  230. Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An EORTC Soft Tissue and Bone Sarcoma Group randomized phase II study.

    Article • Journal of Clinical Oncology, May 2010, American Society of Clinical Oncology (ASCO)

    Professor Pancras C.W. Hogendoorn

  231. First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histologic soft tissue sarcoma (STS) subtypes and as a prognostic factor for MPNST: An EORTC Soft Tissue and Bone Sarcoma Group (STBSG) study.

    Article • Journal of Clinical Oncology, May 2010, American Society of Clinical Oncology (ASCO)

    Professor Pancras C.W. Hogendoorn

  232. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Article • Annals of Oncology, May 2010, Elsevier

    Professor Pancras C.W. Hogendoorn

  233. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Article • Annals of Oncology, May 2010, Elsevier

    Professor Pancras C.W. Hogendoorn

  234. Impact of EWS-ETS Fusion Type on Disease Progression in Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumor: Prospective Results From the Cooperative Euro-E.W.I.N.G. 99 Trial

    Article • Journal of Clinical Oncology, April 2010, American Society of Clinical Oncology (ASCO)

    Professor Pancras C.W. Hogendoorn

  235. Correlation of hypoxic signalling to histological grade and outcome in cartilage tumours

    Article • Histopathology, March 2010, Wiley

    Professor Pancras C.W. Hogendoorn

  236. Langerhans cell histiocytosis: fascinating dynamics of the dendritic cell–macrophage lineage

    Article • Immunological Reviews, February 2010, Wiley

    Professor Pancras C.W. Hogendoorn

  237. Soft tissue sarcomas: introduction to the Virchows Archiv review issue

    Article • Virchows Archiv, February 2010, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  238. Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors

    Article • International Journal of Cancer, January 2010, Wiley

    Prof. Dr. Sjoerd H van der Burg, Professor Pancras C.W. Hogendoorn

  239. Epidemiology of Primary Bone Tumors and Economical Aspects of Bone Metastases

    Article • January 2010, Elsevier

    Professor Pancras C.W. Hogendoorn

  240. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas

    Article • European Journal of Cancer, January 2010, Elsevier

    Professor Pancras C.W. Hogendoorn

  241. Erratum: Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways

    Article • British Journal of Cancer, December 2009, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  242. Improved diagnosis and treatment of soft tissue sarcoma patients after implementation of national guidelines: A population-based study

    Article • European Journal of Surgical Oncology, December 2009, Elsevier

    Professor Pancras C.W. Hogendoorn

  243. Sdhd and Sdhd/H19 Knockout Mice Do Not Develop Paraganglioma or Pheochromocytoma

    Article • PLOS One, November 2009, PLOS

    Professor Pancras C.W. Hogendoorn

  244. A balanced t(5;17) (p15;q22-23) in chondroblastoma: frequency of the re-arrangement and analysis of the candidate genes

    Article • BMC Cancer, November 2009, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  245. Genome‐wide transcriptome analyses reveal p53 inactivation mediated loss of miR‐34a expression in malignant peripheral nerve sheath tumours

    Article • The Journal of Pathology, November 2009, Wiley

    Professor Pancras C.W. Hogendoorn

  246. Prognostic factors in pulmonary metastasized high‐grade osteosarcoma

    Article • Pediatric Blood & Cancer, November 2009, Wiley

    Professor Pancras C.W. Hogendoorn

  247. Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways

    Article • British Journal of Cancer, November 2009, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  248. Dedifferentiated peripheral chondrosarcomas: regulation of EXT-downstream molecules and differentiation-related genes

    Article • Modern Pathology, November 2009, Elsevier

    Professor Pancras C.W. Hogendoorn

  249. The Journal of Pathology 2008 Jeremy Jass Prize for Research Excellence in Pathology

    Article • The Journal of Pathology, October 2009, Wiley

    Professor Pancras C.W. Hogendoorn

  250. Imatinib Mesylate in Patients with WHO B3 Thymomas and Thymic Carcinomas

    Article • Journal of Thoracic Oncology, October 2009, Elsevier

    Professor Pancras C.W. Hogendoorn

  251. Molecular characterization of commonly used cell lines for bone tumor research: A trans‐European EuroBoNet effort

    Article • Genes Chromosomes and Cancer, September 2009, Wiley

    Professor Pancras C.W. Hogendoorn

  252. Molecular pathology of sarcomas: concepts and clinical implications

    Article • Virchows Archiv, September 2009, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  253. Inactive Wnt/β-catenin pathway in conventional high-grade osteosarcoma

    Article • The Journal of Pathology, September 2009, Wiley

    Professor Marcel Karperien, Professor Pancras C.W. Hogendoorn

  254. Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro

    Article • Journal of Cellular and Molecular Medicine, September 2009, Wiley

    Professor Pancras C.W. Hogendoorn

  255. Benign Cartilaginous Tumors of Bone

    Article • Advances in Anatomic Pathology, September 2009, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  256. Primary lymphoma of bone: extranodal lymphoma with favourable survival independent of germinal centre, post-germinal centre or indeterminate phenotype

    Article • Journal of Clinical Pathology, September 2009, BMJ

    Professor Pancras C.W. Hogendoorn

  257. 275 Taxanes in angiosarcomas

    Article • European Journal of Cancer Supplements, September 2009, Elsevier

    Professor Pancras C.W. Hogendoorn

  258. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2

    Article • The Journal of Pathology, August 2009, Wiley

    Professor Pancras C.W. Hogendoorn

  259. Running GAGs: myxoid matrix in tumor pathology revisited

    Article • Virchows Archiv, August 2009, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  260. Absence of Progression As Assessed by Response Evaluation Criteria in Solid Tumors Predicts Survival in Advanced GI Stromal Tumors Treated With Imatinib Mesylate: The Intergroup EORTC-ISG-AGITG Phase III Trial

    Article • Journal of Clinical Oncology, August 2009, American Society of Clinical Oncology (ASCO)

    Professor Pancras C.W. Hogendoorn

  261. Gastrointestinal Stromal Tumors I: Pathology, Pathobiology, Primary Therapy, and Surgical Issues

    Article • Seminars in Oncology, August 2009, Elsevier

    Professor Pancras C.W. Hogendoorn

  262. Kinome Profiling of Chondrosarcoma Reveals Src-Pathway Activity and Dasatinib as Option for Treatment

    Article • Cancer Research, July 2009, American Association for Cancer Research (AACR)

    Professor Pancras C.W. Hogendoorn

  263. Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix

    Article • Journal of Cellular and Molecular Medicine, July 2009, Wiley

    Professor Pancras C.W. Hogendoorn

  264. Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

    Article • Cancer Research, July 2009, American Association for Cancer Research (AACR)

    Professor Pancras C.W. Hogendoorn

  265. Cell Cycle/Apoptosis Molecule Expression Correlates with Imatinib Response in Patients with Advanced Gastrointestinal Stromal Tumors

    Article • Clinical Cancer Research, June 2009, American Association for Cancer Research (AACR)

    Professor Pancras C.W. Hogendoorn

  266. Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition

    Article • The Journal of Pathology, June 2009, Wiley

    Professor Pancras C.W. Hogendoorn

  267. Sclerostin in Mineralized Matrices and van Buchem Disease

    Article • Journal of Dental Research, June 2009, SAGE Publications

    Professor Pancras C.W. Hogendoorn

  268. Similar gene expression profiles of sporadic, PGL2-, and SDHD-linked paragangliomas suggest a common pathway to tumorigenesis

    Article • BMC Medical Genomics, May 2009, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  269. Genomic Profiling of Chondrosarcoma: Chromosomal Patterns in Central and Peripheral Tumors

    Article • Clinical Cancer Research, April 2009, American Association for Cancer Research (AACR)

    Professor Pancras C.W. Hogendoorn

  270. Extra‐abdominal subcutaneous metastasis of a gastrointestinal stromal tumor: report of a case and a review of the literature

    Article • Journal of Cutaneous Pathology, March 2009, Wiley

    Professor Pancras C.W. Hogendoorn

  271. The molecular and cellular basis of exostosis formation in hereditary multiple exostoses

    Article • International Journal of Experimental Pathology, March 2009, Wiley

    Professor Pancras C.W. Hogendoorn

  272. The NFATc2 Gene Is Involved in a Novel Cloned Translocation in a Ewing Sarcoma Variant That Couples Its Function in Immunology to Oncology

    Article • Clinical Cancer Research, March 2009, American Association for Cancer Research (AACR)

    Professor Pancras C.W. Hogendoorn

  273. Aberrant Heparan Sulfate Proteoglycan Localization, Despite Normal Exostosin, in Central Chondrosarcoma

    Article • American Journal Of Pathology, March 2009, Elsevier

    Professor Pancras C.W. Hogendoorn

  274. Superior performance of liquid-based versus conventional cytology in a population-based cervical cancer screening program

    Article • Gynecologic Oncology, March 2009, Elsevier

    Professor Pancras C.W. Hogendoorn

  275. Genomic instability in giant cell tumor of bone. A study of 52 cases using DNA ploidy, relocalization FISH, and array‐CGH analysis

    Article • Genes Chromosomes and Cancer, February 2009, Wiley

    Professor Pancras C.W. Hogendoorn

  276. Telomere‐associated proteins: cross‐talk between telomere maintenance and telomere‐lengthening mechanisms

    Article • The Journal of Pathology, January 2009, Wiley

    Professor Pancras C.W. Hogendoorn

  277. Assessment of Interobserver Variability and Histologic Parameters to Improve Reliability in Classification and Grading of Central Cartilaginous Tumors

    Article • The American Journal of Surgical Pathology, January 2009, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  278. CD33+ CD14− Phenotype Is Characteristic of Multinuclear Osteoclast‐Like Cells in Giant Cell Tumor of Bone

    Article • Journal of Bone and Mineral Research, January 2009, Oxford University Press (OUP)

    Professor Pancras C.W. Hogendoorn

  279. Imaging Multidrug Resistance in Osteosarcoma: A Pre-clinical Approach Using an Orthotopic Animal Model

    Article • January 2009, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  280. No genomic aberrations in Langerhans cell histiocytosis as assessed by diverse molecular technologies

    Article • Genes Chromosomes and Cancer, December 2008, Wiley

    Professor Pancras C.W. Hogendoorn

  281. Reduced leucocyte cholesteryl ester transfer protein expression in acute coronary syndromes

    Article • Journal of Internal Medicine, November 2008, Wiley

    Professor Pancras C.W. Hogendoorn

  282. The cytotoxic effect of phenol and ethanol on the chondrosarcoma-derived cell line OUMS-27: AN IN VITRO EXPERIMENT

    Article • Journal of Bone and Joint Surgery - British Volume, November 2008, Bone & Joint

    Professor Pancras C.W. Hogendoorn

  283. Paclitaxel in patients with advanced angiosarcomas of soft tissue: A retrospective study of the EORTC soft tissue and bone sarcoma group

    Article • European Journal of Cancer, November 2008, Elsevier

    Professor Pancras C.W. Hogendoorn

  284. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways

    Article • Molecular Immunology, September 2008, Elsevier

    Professor Pancras C.W. Hogendoorn

  285. Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate

    Article • European Journal of Cancer, September 2008, Elsevier

    Professor Pancras C.W. Hogendoorn

  286. A chondrogenic gene expression signature in mesenchymal stem cells is a classifier of conventional central chondrosarcoma

    Article • The Journal of Pathology, August 2008, Wiley

    Professor Pancras C.W. Hogendoorn

  287. Results of Diagnostic Review in Pediatric Bone Tumors and Tumorlike Lesions

    Article • Journal of Pediatric Orthopaedics, July 2008, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  288. Critical illness VR rehabilitation device (X-VR-D): Evaluation of the potential use for early clinical rehabilitation

    Article • Journal of Electromyography and Kinesiology, June 2008, Elsevier

    Professor Pancras C.W. Hogendoorn

  289. Aromatase inhibition in patients with recurrent and/or metastatic chondrosarcoma (CS)

    Article • Journal of Clinical Oncology, May 2008, American Society of Clinical Oncology (ASCO)

    Professor Pancras C.W. Hogendoorn

  290. Prognostic and predictive factors for outcome to first-line ifosfamide-containing therapy (IFM) in patients (pts) with advanced soft tissue sarcomas (STS) treated in EORTC-STBSG studies

    Article • Journal of Clinical Oncology, May 2008, American Society of Clinical Oncology (ASCO)

    Professor Pancras C.W. Hogendoorn

  291. Survival after recurrent osteosarcoma: Data from three European Osteosarcoma Intergroup (EOI) randomized controlled

    Article • Journal of Clinical Oncology, May 2008, American Society of Clinical Oncology (ASCO)

    Professor Pancras C.W. Hogendoorn

  292. The diagnostic utility of DOG1 expression in KIT-negative GIST

    Article • Journal of Clinical Oncology, May 2008, American Society of Clinical Oncology (ASCO)

    Professor Pancras C.W. Hogendoorn

  293. The end of adjuvant chemotherapy (adCT) era with doxorubicin-based regimen in resected high-grade soft tissue sarcoma (STS): Pooled analysis of the two STBSG-EORTC phase III clinical trials

    Article • Journal of Clinical Oncology, May 2008, American Society of Clinical Oncology (ASCO)

    Professor Pancras C.W. Hogendoorn

  294. The Clinical Approach Towards Chondrosarcoma

    Article • The Oncologist, May 2008, Oxford University Press (OUP)

    Professor Pancras C.W. Hogendoorn

  295. Gastrointestinal stromal tumors: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

    Article • Annals of Oncology, May 2008, Elsevier

    Professor Pancras C.W. Hogendoorn

  296. Soft tissue sarcomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

    Article • Annals of Oncology, May 2008, Elsevier

    Professor Pancras C.W. Hogendoorn

  297. A Phase II Study of Gefitinib for Patients with Advanced HER-1 Expressing Synovial Sarcoma Refractory to Doxorubicin-Containing Regimens

    Article • The Oncologist, April 2008, Oxford University Press (OUP)

    Professor Pancras C.W. Hogendoorn

  298. The Clinical Approach Towards Chondrosarcoma

    Article • The Oncologist, March 2008, Oxford University Press (OUP)

    Professor Pancras C.W. Hogendoorn

  299. Myxoid tumours of soft tissue: the so‐called myxoid extracellular matrix is heterogeneous in composition

    Article • Histopathology, February 2008, Wiley

    Professor Pancras C.W. Hogendoorn

  300. Telomere biology in giant cell tumour of bone

    Article • The Journal of Pathology, February 2008, Wiley

    Professor Pancras C.W. Hogendoorn

  301. Incidence of Biopsy-Proven Bone Tumors in Children

    Article • Journal of Pediatric Orthopaedics, January 2008, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  302. Lymphatics and bone

    Article • Human Pathology, January 2008, Elsevier

    Professor Pancras C.W. Hogendoorn

  303. Neurocutaneous Disorders Phakomatoses and Hamartoneoplastic Syndromes

    Article • January 2008, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  304. EWSR1-CREB1 and EWSR1-ATF1 Fusion Genes in Angiomatoid Fibrous Histiocytoma

    Article • Clinical Cancer Research, December 2007, American Association for Cancer Research (AACR)

    Professor Pancras C.W. Hogendoorn

  305. Frequent deletion of the CDKN2A locus in chordoma: analysis of chromosomal imbalances using array comparative genomic hybridisation

    Article • British Journal of Cancer, December 2007, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  306. CT‐guided, COBRA‐FISH‐assisted diagnosis of well‐differentiated liposarcoma (inflammatory subtype) of the retroperitoneum

    Article • Histopathology, August 2007, Wiley

    Professor Pancras C.W. Hogendoorn

  307. Increased HIF1α in SDH and FH deficient tumors does not cause microsatellite instability

    Article • International Journal of Cancer, July 2007, Wiley

    Professor Pancras C.W. Hogendoorn

  308. Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study

    Article • Journal of Clinical Oncology, July 2007, American Society of Clinical Oncology (ASCO)

    Professor Pancras C.W. Hogendoorn

  309. Does parosteal liposarcoma differ from other atypical lipomatous tumors/well-differentiated liposarcomas? A molecular cytogenetic study using combined multicolor COBRA-FISH karyotyping and array-based comparative genomic hybridization

    Article • Cancer Genetics and Cytogenetics, July 2007, Elsevier

    Professor Pancras C.W. Hogendoorn

  310. The role of noncartilage‐specific molecules in differentiation of cartilaginous tumors

    Article • Cancer, June 2007, Wiley

    Professor Pancras C.W. Hogendoorn

  311. MR imaging characteristics in primary lymphoma of bone with emphasis on non-aggressive appearance

    Article • Skeletal Radiology, June 2007, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  312. Functional imaging of multidrug resistance in an orthotopic model of osteosarcoma using 99mTc-sestamibi

    Article • European Journal of Pediatrics, June 2007, Springer Science + Business Media

    Dr. Mick Welling, Professor Pancras C.W. Hogendoorn

  313. Differences in telomerase expression by the CD1a+ cells in Langerhans cell histiocytosis reflect the diverse clinical presentation of the disease

    Article • The Journal of Pathology, May 2007, Wiley

    Professor Pancras C.W. Hogendoorn

  314. The Role of EXT1 in Nonhereditary Osteochondroma: Identification of Homozygous Deletions

    Article • JNCI Journal of the National Cancer Institute, March 2007, Oxford University Press (OUP)

    Professor Pancras C.W. Hogendoorn

  315. Identification of markers to characterize and sort human articular chondrocytes with enhanced in vitro chondrogenic capacity

    Article • Arthritis & Rheumatism, January 2007, Wiley

    Professor Pancras C.W. Hogendoorn

  316. Improvement in Histologic Response But Not Survival in Osteosarcoma Patients Treated With Intensified Chemotherapy: A Randomized Phase III Trial of the European Osteosarcoma Intergroup

    Article • JNCI Journal of the National Cancer Institute, January 2007, Oxford University Press (OUP)

    Mr Matthew R Sydes, Professor Pancras C.W. Hogendoorn

  317. Decreased EXT expression and intracellular accumulation of heparan sulphate proteoglycan in osteochondromas and peripheral chondrosarcomas

    Article • The Journal of Pathology, January 2007, Wiley

    Professor Pancras C.W. Hogendoorn

  318. Detection and molecular cytogenetic characterization of a novel ring chromosome in a histological variant of Ewing sarcoma

    Article • Cancer Genetics and Cytogenetics, January 2007, Elsevier

    Professor Pancras C.W. Hogendoorn

  319. Expression of Cellular FLICE Inhibitory Protein, Caspase-8, and Protease Inhibitor-9 in Ewing Sarcoma and Implications for Susceptibility to Cytotoxic Pathways

    Article • Clinical Cancer Research, January 2007, American Association for Cancer Research (AACR)

    Professor Pancras C.W. Hogendoorn

  320. Basic fibroblast growth factor and fibroblastic growth factor receptor–1 may contribute to head and neck paraganglioma development by an autocrine or paracrine mechanism

    Article • Human Pathology, January 2007, Elsevier

    Professor Pancras C.W. Hogendoorn

  321. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: A phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

    Article • European Journal of Cancer, January 2007, Elsevier

    Professor Pancras C.W. Hogendoorn

  322. Differences in Telomerase Expression by the CD1a+ Cells in Langerhans Cell Histiocytosis Reflects the Diverse Clinical Presentation of the Disease

    Article • Clinical Immunology, January 2007, Elsevier

    Professor Pancras C.W. Hogendoorn

  323. SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular development

    Article • Developmental Dynamics, December 2006, Wiley

    Professor Pancras C.W. Hogendoorn

  324. Osteosarcoma Derived from Cultured Mesenchymal Stem Cells.

    Article • Blood, November 2006, American Society of Hematology

    Professor Pancras C.W. Hogendoorn

  325. Sarcoma Derived from Cultured Mesenchymal Stem Cells

    Article • Stem Cells, October 2006, Oxford University Press (OUP)

    Professor Pancras C.W. Hogendoorn

  326. Multidrug resistance mediated by ABC transporters in osteosarcoma cell lines: mRNA analysis and functional radiotracer studies

    Article • Nuclear Medicine and Biology, October 2006, Elsevier

    Dr. Mick Welling, Professor Pancras C.W. Hogendoorn

  327. Pathology of primary malignant bone and cartilage tumours

    Article • International Orthopaedics, August 2006, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  328. Chondroid lipoma: findings on radiography and MRI (2006:7b)

    Article • European Radiology, August 2006, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  329. Array‐comparative genomic hybridization of central chondrosarcoma

    Article • Cancer, July 2006, Wiley

    Professor Pancras C.W. Hogendoorn

  330. Giant cell tumors of the tendon sheath may present radiologically as intrinsic osseous lesions

    Article • European Radiology, June 2006, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  331. Peripheral chondrosarcoma progression is accompanied by decreased Indian Hedgehog signalling

    Article • The Journal of Pathology, June 2006, Wiley

    Professor Pancras C.W. Hogendoorn

  332. EXT‐related pathways are not involved in the pathogenesis of dysplasia epiphysealis hemimelica and metachondromatosis

    Article • The Journal of Pathology, April 2006, Wiley

    Professor Pancras C.W. Hogendoorn

  333. Nora’s lesion, a distinct radiological entity?

    Article • Skeletal Radiology, April 2006, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  334. Molecular cytogenetic characterization of four previously established and two newly established Ewing sarcoma cell lines

    Article • Cancer Genetics and Cytogenetics, April 2006, Elsevier

    Professor Pancras C.W. Hogendoorn

  335. Clinico-histologic parameters of osteosarcoma patients with late relapse

    Article • European Journal of Cancer, March 2006, Elsevier

    Mr Matthew R Sydes, Professor Pancras C.W. Hogendoorn

  336. 23 Assessment of molecular determinants of development and treatment efficacy in radiation induced sarcoma (RIS) — eortc translational research project 01/01

    Article • Radiotherapy and Oncology, March 2006, Elsevier

    Professor Pancras C.W. Hogendoorn

  337. Soft tissue pathology

    Article • Current Diagnostic Pathology, February 2006, Elsevier

    Professor Pancras C.W. Hogendoorn

  338. Brachyury and chordoma: the chondroid–chordoid dilemma resolved?

    Article • The Journal of Pathology, January 2006, Wiley

    Professor Pancras C.W. Hogendoorn

  339. Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model

    Article • Modern Pathology, January 2006, Elsevier

    Professor Pancras C.W. Hogendoorn

  340. F.139. Expression and Functional Relevance of cFLIP, PI-9 and Caspase 8 in Ewing's Sarcoma: Implications for Immunotherapy

    Article • Clinical Immunology, January 2006, Elsevier

    Professor Pancras C.W. Hogendoorn

  341. Tumor Cell Plasticity in Ewing Sarcoma, an Alternative Circulatory System Stimulated by Hypoxia

    Article • Cancer Research, December 2005, American Association for Cancer Research (AACR)

    Professor Pancras C.W. Hogendoorn

  342. Central high-grade osteosarcoma of bone: Diagnostic and genetic considerations

    Article • Current Diagnostic Pathology, December 2005, Elsevier

    Professor Pancras C.W. Hogendoorn

  343. Incidence of gastrointestinal stromal tumours is underestimated: Results of a nation-wide study

    Article • European Journal of Cancer, December 2005, Elsevier

    Professor Pancras C.W. Hogendoorn

  344. Limited Rescue of Osteoclast‐Poor Osteopetrosis After Successful Engraftment by Cord Blood From an Unrelated Donor

    Article • Journal of Bone and Mineral Research, December 2005, Oxford University Press (OUP)

    Professor Pancras C.W. Hogendoorn

  345. The histopathological differential diagnosis of mesenchymal tumours of the skin

    Article • Current Diagnostic Pathology, December 2005, Elsevier

    Professor Pancras C.W. Hogendoorn

  346. Estrogen Signaling Is Active in Cartilaginous Tumors: Implications for Antiestrogen Therapy as Treatment Option of Metastasized or Irresectable Chondrosarcoma

    Article • Clinical Cancer Research, November 2005, American Association for Cancer Research (AACR)

    Professor Pancras C.W. Hogendoorn

  347. TGF‐β1 drives partial myofibroblastic differentiation in chondromyxoid fibroma of bone

    Article • The Journal of Pathology, November 2005, Wiley

    Professor Pancras C.W. Hogendoorn

  348. Accuracy of radiography in grading and tissue-specific diagnosis—a study of 200 consecutive bone tumors of the hand

    Article • Skeletal Radiology, October 2005, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  349. Desmoplastic fibroma of bone: an immunohistochemical study including -catenin expression and mutational analysis for -catenin

    Article • Human Pathology, September 2005, Elsevier

    Professor Pancras C.W. Hogendoorn

  350. Initial and Late Resistance to Imatinib in Advanced Gastrointestinal Stromal Tumors Are Predicted by Different Prognostic Factors: A European Organisation for Research and Treatment of Cancer–Italian Sarcoma Group–Australasian Gastrointestinal Trials G...

    Article • Journal of Clinical Oncology, August 2005, American Society of Clinical Oncology (ASCO)

    Professor Pancras C.W. Hogendoorn

  351. Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment

    Article • The Lancet Oncology, August 2005, Elsevier

    Professor Pancras C.W. Hogendoorn

  352. cDNA expression profiling of chondrosarcomas: Ollier disease resembles solitary tumours and alteration in genes coding for components of energy metabolism occurs with increasing grade

    Article • The Journal of Pathology, July 2005, Wiley

    Professor Pancras C.W. Hogendoorn

  353. Corrections to “Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO”

    Article • Annals of Oncology, June 2005, Elsevier

    Professor Pancras C.W. Hogendoorn

  354. Consensus meeting for the management of gastrointestinal stromal tumors
 Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

    Article • Annals of Oncology, April 2005, Elsevier

    Professor Pancras C.W. Hogendoorn

  355. Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis

    Article • Journal of Experimental Medicine, March 2005, Rockefeller University Press

    Professor Pancras C.W. Hogendoorn

  356. The use of Bcl-2 and PTHLH immunohistochemistry in the diagnosis of peripheral chondrosarcoma in a clinicopathological setting

    Article • Virchows Archiv, March 2005, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  357. Prenatal Detection of Orbital Rhabdomyosarcoma

    Article • Archives of Ophthalmology, February 2005, American Medical Association (AMA)

    Professor Pancras C.W. Hogendoorn

  358. Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas

    Article • The Journal of Pathology, January 2005, Wiley

    Professor Pancras C.W. Hogendoorn

  359. Chondromyxoid fibroma resemblesin vitro chondrogenesis, but differs in expression of signalling molecules

    Article • The Journal of Pathology, January 2005, Wiley

    Paul HC Eilers, Professor Pancras C.W. Hogendoorn

  360. Bifurcation of the femur with tibial agenesis and additional anomalies

    Article • American Journal of Medical Genetics Part A, January 2005, Wiley

    Professor Pancras C.W. Hogendoorn

  361. Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study

    Article • European Journal of Cancer, January 2005, Elsevier

    Professor Pancras C.W. Hogendoorn

  362. Mutation screening of EXT1 and EXT2 by direct sequence analysis and MLPA in patients with multiple osteochondromas: splice site mutations and exonic deletions account for more than half of the mutations

    Article • European Journal of Human Genetics, December 2004, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  363. MRI of Adamantinoma of Long Bones in Correlation with Histopathology

    Article • American Journal of Roentgenology, December 2004, American Roentgen Ray Society

    Professor Pancras C.W. Hogendoorn

  364. Multiple Osteochondromas: Clinicopathological and Genetic Spectrum and Suggestions for Clinical Management

    Article • Hereditary Cancer in Clinical Practice, November 2004, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  365. Aggressive angiomyxoma: a clinicopathological and immunohistochemical study of 11 cases with long-term follow-up

    Article • Virchows Archiv, November 2004, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  366. Enchondromatosis (Ollier disease, Maffucci syndrome) is not caused by the PTHR1 mutation p.R150C

    Article • Human Mutation, November 2004, Hindawi Publishing Corporation

    Professor Pancras C.W. Hogendoorn

  367. Primary synovial sarcoma of the heart: a cytogenetic and molecular genetic analysis combining RT-PCR and COBRA-FISH of a case with a complex karyotype

    Article • Modern Pathology, November 2004, Elsevier

    Professor Pancras C.W. Hogendoorn

  368. Soft-Tissue Tumors: Value of Static and Dynamic Gadopentetate Dimeglumine–enhanced MR Imaging in Prediction of Malignancy

    Article • Radiology, November 2004, Radiological Society of North America (RSNA)

    Professor Pancras C.W. Hogendoorn

  369. Magnetic resonance imaging of knee cartilage using a water selective balanced steady‐state free precession sequence

    Article • Journal of Magnetic Resonance Imaging, October 2004, Wiley

    Professor Pancras C.W. Hogendoorn

  370. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

    Article • The Lancet, September 2004, Elsevier

    Professor Pancras C.W. Hogendoorn

  371. Multicolor fluorescence in situ hybridization analysis of a synovial sarcoma of the larynx with a t(X;18)(p11.2;q11.2) and trisomies 2 and 8

    Article • Cancer Genetics and Cytogenetics, August 2004, Elsevier

    Professor Pancras C.W. Hogendoorn

  372. Cathepsin K Is the Principal Protease in Giant Cell Tumor of Bone

    Article • American Journal Of Pathology, August 2004, Elsevier

    Professor Pancras C.W. Hogendoorn

  373. Changing concepts in the pathological basis of soft tissue and bone sarcoma treatment

    Article • European Journal of Cancer, July 2004, Elsevier

    Professor Pancras C.W. Hogendoorn

  374. A phase II study of ET-743/trabectedin (`Yondelis') for patients with advanced gastrointestinal stromal tumours

    Article • European Journal of Cancer, June 2004, Elsevier

    Professor Pancras C.W. Hogendoorn

  375. Solitary fibrous tumour: the emerging clinicopathologic spectrum of an entity and its differential diagnosis

    Article • Current Diagnostic Pathology, June 2004, Elsevier

    Professor Pancras C.W. Hogendoorn

  376. Expression Profiling of t(12;22) Positive Clear Cell Sarcoma of Soft Tissue Cell Lines Reveals Characteristic Up-Regulation of Potential New Marker Genes Including ERBB3

    Article • Cancer Research, May 2004, American Association for Cancer Research (AACR)

    Professor Pancras C.W. Hogendoorn

  377. Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas

    Article • European Journal of Cancer, May 2004, Elsevier

    Professor Pancras C.W. Hogendoorn

  378. Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families

    Article • Oncogene, April 2004, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  379. Chondroma and chondrosarcoma of the larynx

    Article • Current Opinion in Otolaryngology & Head & Neck Surgery, April 2004, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  380. Multiparameter DNA flow‐sorting demonstrates diploidy and SDHD wild‐type gene retention in the sustentacular cell compartment of head and neck paragangliomas: chief cells are the only neoplastic component

    Article • The Journal of Pathology, February 2004, Wiley

    Professor Pancras C.W. Hogendoorn

  381. Molecular analysis of the INK4A/INK4A‐ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression

    Article • The Journal of Pathology, February 2004, Wiley

    Professor Pancras C.W. Hogendoorn

  382. Langerhans cell histiocytosis: A pathologic combination of oncogenesis and immune dysregulation

    Article • Pediatric Blood & Cancer, February 2004, Wiley

    Professor Pancras C.W. Hogendoorn

  383. A distinct phenotype characterizes tumors from a putative genetic trait involving chondrosarcoma and breast cancer occurring in the same patient

    Article • Laboratory Investigation, February 2004, Elsevier

    Professor Pancras C.W. Hogendoorn

  384. Dedifferentiated Adamantinoma With Revertant Mesenchymal Phenotype

    Article • The American Journal of Surgical Pathology, December 2003, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  385. Expression of cartilage growth plate signalling molecules in chondroblastoma

    Article • The Journal of Pathology, November 2003, Wiley

    Professor Pancras C.W. Hogendoorn

  386. SDHD mutations in head and neck paragangliomas result in destabilization of complex II in the mitochondrial respiratory chain with loss of enzymatic activity and abnormal mitochondrial morphology

    Article • The Journal of Pathology, September 2003, Wiley

    Professor Pancras C.W. Hogendoorn

  387. Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target

    Article • European Journal of Cancer, September 2003, Elsevier

    Professor Pancras C.W. Hogendoorn

  388. Pathology of soft tissue sarcomas with emphasis on molecular diagnostic techniques

    Article • European Journal of Cancer Supplements, September 2003, Elsevier

    Professor Pancras C.W. Hogendoorn

  389. Langerhans-cell histiocytosis: neoplasia or unbridled inflammation?

    Article • Trends in Immunology, August 2003, Elsevier

    Professor Pancras C.W. Hogendoorn

  390. Response to Fadeel and Henter: Langerhans cell histiocytosis: a combination of carcinogenesis and inflammation

    Article • Trends in Immunology, August 2003, Elsevier

    Professor Pancras C.W. Hogendoorn

  391. Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma

    Article • European Journal of Human Genetics, July 2003, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  392. G2M arrest, blocked apoptosis, and low growth fraction may explain indolent behavior of head and neck paragangliomas

    Article • Human Pathology, July 2003, Elsevier

    Professor Pancras C.W. Hogendoorn

  393. Aberrant Chemokine Receptor Expression and Chemokine Production by Langerhans Cells Underlies the Pathogenesis of Langerhans Cell Histiocytosis

    Article • Journal of Experimental Medicine, May 2003, Rockefeller University Press

    Professor Pancras C.W. Hogendoorn

  394. Langerhans-cell histiocytosis 'insight into DC biology'

    Article • Trends in Immunology, April 2003, Elsevier

    Professor Pancras C.W. Hogendoorn

  395. Dynamic contrast-enhanced MR imaging in monitoring response to isolated limb perfusion in high-grade soft tissue sarcoma: initial results

    Article • European Radiology, January 2003, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  396. Amplification of 17p11.2∼p12, including PMP22, TOP3A, and MAPK7, in high-grade osteosarcoma

    Article • Cancer Genetics and Cytogenetics, December 2002, Elsevier

    Professor Pancras C.W. Hogendoorn

  397. Clear cell sarcoma of the stomach

    Article • Histopathology, December 2002, Wiley

    Professor Pancras C.W. Hogendoorn

  398. Expression of Cell Cycle–Related Gene Products in Langerhans Cell Histiocytosis

    Article • Journal of Pediatric Hematology/Oncology, December 2002, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  399. Technical Considerations in CT-Guided Radiofrequency Thermal Ablation of Osteoid Osteoma: Tricks of the Trade

    Article • American Journal of Roentgenology, December 2002, American Roentgen Ray Society

    Professor Pancras C.W. Hogendoorn

  400. Hemicortical allograft reconstruction after resection of low-grade malignant bone tumours

    Article • Journal of Bone and Joint Surgery - British Volume, September 2002, Bone & Joint

    Professor Pancras C.W. Hogendoorn

  401. Diagnosis and prognosis of chondrosarcoma of bone

    Article • Expert Review of Molecular Diagnostics, September 2002, Taylor & Francis

    Professor Pancras C.W. Hogendoorn

  402. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup

    Article • European Journal of Cancer, June 2002, Elsevier

    Professor Pancras C.W. Hogendoorn

  403. Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group

    Article • European Journal of Cancer, March 2002, Elsevier

    Professor Pancras C.W. Hogendoorn

  404. Intermediate grade osteosarcoma and chondrosarcoma arising in an osteochondroma. A case report of a patient with hereditary multiple exostoses

    Article • Journal of Clinical Pathology, March 2002, BMJ

    Professor Pancras C.W. Hogendoorn

  405. Diffusion‐weighted MRI in the characterization of soft‐tissue tumors

    Article • Journal of Magnetic Resonance Imaging, February 2002, Wiley

    Professor Pancras C.W. Hogendoorn

  406. Scale‐invariant segmentation of dynamic contrast‐enhanced perfusion MR images with inherent scale selection

    Article • The Journal of Visualization and Computer Animation, February 2002, Wiley

    Professor Pancras C.W. Hogendoorn

  407. Cartilage-forming tumours of bone and soft tissue and their differential diagnosis

    Article • Current Diagnostic Pathology, December 2001, Elsevier

    Professor Pancras C.W. Hogendoorn

  408. Chromosome 9 Alterations and Trisomy 22 in Central Chondrosarcoma: A Cytogenetic and DNA Flow Cytometric Analysis of Chondrosarcoma Subtypes

    Article • Diagnostic Molecular Pathology, December 2001, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  409. High quality RNA isolation from tumours with low cellularity and high extracellular matrix component for cDNA microarrays: application to chondrosarcoma

    Article • Journal of Clinical Pathology, October 2001, BMJ

    Professor Pancras C.W. Hogendoorn

  410. Retain or sacrifice the posterior cruciate ligament in total knee arthroplasty? A histopathological study of the cruciate ligament in osteoarthritic and rheumatoid disease

    Article • Journal of Clinical Pathology, May 2001, BMJ

    Professor Pancras C.W. Hogendoorn

  411. Synovial sarcoma: dynamic contrast-enhanced MR imaging features

    Article • Skeletal Radiology, February 2001, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  412. The histopathological differential diagnosis of gastrointestinal stromal tumours

    Article • Journal of Clinical Pathology, February 2001, BMJ

    Professor Pancras C.W. Hogendoorn

  413. Adamantinoma-like Ewing's sarcoma and Ewing's-like adamantinoma. The t(11; 22), t(21; 22) status

    Article • The Journal of Pathology, January 2001, Wiley

    Professor Pancras C.W. Hogendoorn

  414. Malignant melanoma is genetically distinct from clear cell sarcoma of tendons and aponeurosis (malignant melanoma of soft parts)

    Article • British Journal of Cancer, January 2001, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  415. An association between cartilaginous tumours and breast cancer in the national pathology registration in The Netherlands points towards a possible genetic trait

    Article • The Journal of Pathology, January 2001, Wiley

    Professor Pancras C.W. Hogendoorn

  416. Chondrosarcoma is not characterized by detectable telomerase activity

    Article • The Journal of Pathology, January 2001, Wiley

    Professor Pancras C.W. Hogendoorn

  417. Human granzyme B mediates cartilage proteoglycan degradation and is expressed at the invasive front of the synovium in rheumatoid arthritis

    Article • Rheumatology, January 2001, Oxford University Press (OUP)

    Professor Pancras C.W. Hogendoorn

  418. Retroperitoneal extraskeletal osteosarcoma

    Article • Journal of Clinical Pathology, January 2001, BMJ

    Professor Pancras C.W. Hogendoorn

  419. Assessment of the influence of preoperative chemotherapy in patients with osteosarcoma by dynamic contrast-enhanced MRI using pharmacokinetic modeling

    Article • January 2001, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  420. Up-Regulation of PTHrP and Bcl-2 Expression Characterizes the Progression of Osteochondroma towards Peripheral Chondrosarcoma and Is a Late Event in Central Chondrosarcoma

    Article • Laboratory Investigation, December 2000, Elsevier

    Professor Pancras C.W. Hogendoorn

  421. Infantile‐type digital fibromatosis tumour in an adult

    Article • British Journal of Dermatology, November 2000, Oxford University Press (OUP)

    Professor Pancras C.W. Hogendoorn

  422. Near-Haploidy and Subsequent Polyploidization Characterize the Progression of Peripheral Chondrosarcoma

    Article • American Journal Of Pathology, November 2000, Elsevier

    Professor Pancras C.W. Hogendoorn

  423. Malignant progression in multiple enchondromatosis (Ollier's disease): An autopsy-based molecular genetic study

    Article • Human Pathology, October 2000, Elsevier

    Professor Pancras C.W. Hogendoorn

  424. Detection of areas with viable remnant tumor in postchemotherapy patients with Ewing’s sarcoma by dynamic contrast-enhanced MRI using pharmacokinetic modeling

    Article • Magnetic Resonance Imaging, June 2000, Elsevier

    Professor Pancras C.W. Hogendoorn

  425. MR imaging of clear cell sarcoma (malignant melanoma of the soft parts): a multicenter correlative MRI-pathology study of 21 cases and literature review

    Article • Skeletal Radiology, April 2000, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  426. Re. Review Article entitled ?The neoplastic pathogenesis of solitary and multiple osteochondromas?

    Article • The Journal of Pathology, March 2000, Wiley

    Professor Pancras C.W. Hogendoorn

  427. Cartilaginous Tumors: Fast Contrast-enhanced MR Imaging

    Article • Radiology, February 2000, Radiological Society of North America (RSNA)

    Professor Pancras C.W. Hogendoorn

  428. Bone tumors

    Article • European Radiology, January 2000, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  429. An update of diagnostic strategies using molecular genetic and magnetic resonance imaging techniques for musculoskeletal tumors

    Article • Current Opinion in Rheumatology, January 2000, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  430. Soft Tissue Tumours of the Retroperitoneum

    Article • Sarcoma, January 2000, Wiley

    Professor Pancras C.W. Hogendoorn

  431. Molecular genetic characterization of both components of a dedifferentiated chondrosarcoma, with implications for its histogenesis

    Article • The Journal of Pathology, December 1999, Wiley

    Professor Pancras C.W. Hogendoorn

  432. Primary non-Hodgkin’s lymphoma of bone: a clinicopathological investigation of 60 cases

    Article • Leukemia, December 1999, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  433. Chondrosarcoma of the phalanx

    Article • Cancer, November 1999, Wiley

    Professor Pancras C.W. Hogendoorn

  434. Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma

    Article • Genes Chromosomes and Cancer, November 1999, Wiley

    Professor Pancras C.W. Hogendoorn

  435. A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma

    Article • Annals of Oncology, October 1999, Elsevier

    Professor Pancras C.W. Hogendoorn

  436. Myxoid tumours of soft tissue

    Article • Histopathology, October 1999, Wiley

    Professor Pancras C.W. Hogendoorn

  437. Neoadjuvant Chemotherapy With Doxorubicin and Cisplatin in Malignant Fibrous Histiocytoma of Bone: A European Osteosarcoma Intergroup Study

    Article • Journal of Clinical Oncology, October 1999, American Society of Clinical Oncology (ASCO)

    Professor Pancras C.W. Hogendoorn

  438. EXT-Mutation Analysis and Loss of Heterozygosity in Sporadic and Hereditary Osteochondromas and Secondary Chondrosarcomas

    Article • The American Journal of Human Genetics, September 1999, Elsevier

    Professor Pancras C.W. Hogendoorn

  439. Diagnostic and prognostic implications of the unfolding molecular biology of bone and soft tissue tumours.

    Article • Journal of Clinical Pathology, July 1999, BMJ

    Professor Pancras C.W. Hogendoorn

  440. Adenocarcinoma arising within a tailgut cyst: clinicopathological description and follow up of an unusual case.

    Article • Journal of Clinical Pathology, April 1999, BMJ

    Professor Pancras C.W. Hogendoorn

  441. Translocation (11;22)(q24;q12) in a small cell tumor of the thigh in a 2-year-old boy: Immunohistology, cytogenetics, molecular genetics, and review of the literature*1

    Article • Human Pathology, March 1999, Elsevier

    Professor Pancras C.W. Hogendoorn

  442. Segmentation of Dynamic Contrast-Enhanced MR-Images of Post Chemotherapy Ewing’s Sarcoma with a Pharmacokinetic Model and a Neural Network

    Article • January 1999, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  443. Ring Chromosome 4 as the Sole Cytogenetic Anomaly in a Chondroblastoma

    Article • Cancer Genetics and Cytogenetics, September 1998, Elsevier

    Professor Pancras C.W. Hogendoorn

  444. Musculoskeletal tumors: does fast dynamic contrast-enhanced subtraction MR imaging contribute to the characterization?

    Article • Radiology, September 1998, Radiological Society of North America (RSNA)

    Professor Pancras C.W. Hogendoorn

  445. Clear cell sarcoma of tendons and aponeuroses (malignant melanoma of soft parts) and cutaneous melanoma: exploring the histogenetic relationship between these two clinicopathological entities

    Article • The Journal of Pathology, September 1998, Wiley

    Professor Pancras C.W. Hogendoorn

  446. Local recurrence of a phyllodes tumour of the breast presenting with widespread differentiation to a telangiectatic osteosarcoma

    Article • Journal of Clinical Pathology, September 1998, BMJ

    Professor Pancras C.W. Hogendoorn

  447. Maligne Knorpeltumoren

    Article • Der Radiologe, June 1998, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  448. Chondroblastic osteosarcoma: characterisation by gadolinium-enhanced MR imaging correlated with histopathology

    Article • Skeletal Radiology, March 1998, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  449. Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing's sarcoma: review of current imaging modalities

    Article • Skeletal Radiology, February 1998, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  450. How is the mutational status for tumor suppressors p53 and p16INK4A in MFH of the bone?

    Article • Cancer Letters, January 1998, Elsevier

    Professor Pancras C.W. Hogendoorn

  451. Expression of growth factors and their receptors in adamantinoma of long bones and the implication for its histogenesis

    Article • The Journal of Pathology, January 1998, Wiley

    Professor Pancras C.W. Hogendoorn

  452. MR imaging based strategies in limb salvage surgery for osteosarcoma of the distal femur

    Article • Skeletal Radiology, November 1997, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  453. Usefulness of radiography in differentiating enchondroma from central grade 1 chondrosarcoma.

    Article • American Journal of Roentgenology, October 1997, American Roentgen Ray Society

    Professor Pancras C.W. Hogendoorn

  454. Cytogenetic analysis of adamantinoma of long bones: Further indications for a common histogenesis with osteofibrous dysplasia

    Article • Cancer Genetics and Cytogenetics, August 1997, Elsevier

    Professor Pancras C.W. Hogendoorn

  455. Absence of Epstein-Barr virus (EBV) in a gastrointestinal stromal cell tumour (GIST) in an adult human immunodeficiency virus-seropositive patient with past EBV infection

    Article • European Journal of Gastroenterology & Hepatology, July 1997, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  456. Skin Metastases of Osteogenic Sarcoma

    Article • Journal of Pediatric Hematology/Oncology, May 1997, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  457. Does magnetic resonance imaging make a difference for patients with musculoskeletal sarcoma?

    Article • British Journal of Radiology, April 1997, Oxford University Press (OUP)

    Professor Pancras C.W. Hogendoorn

  458. Malignant astrocytoma-derived region of common amplification in chromosomal band 17p12 is frequently amplified in high-grade osteosarcomas

    Article • Genes Chromosomes and Cancer, April 1997, Wiley

    Professor Pancras C.W. Hogendoorn

  459. Distribution of extracellular matrix components in adamantinoma of long bones suggests fibrous-to-epithelial transformation

    Article • Human Pathology, February 1997, Elsevier

    Professor Pancras C.W. Hogendoorn

  460. Molecular Identification of a Partial Hydatidiform Mole

    Article • Diagnostic Molecular Pathology, February 1997, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  461. Late Malignant Transformation of a Benign Giant-Cell Tumor of Bone. A Case Report*

    Article • Journal of Bone and Joint Surgery, February 1997, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  462. Accuracy of the Jamshidi Trocar Biopsy in the Diagnosis of Bone Tumors

    Article • Clinical Orthopaedics and Related Research, January 1997, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  463. Tumor-associated eosinophilic infiltrate of cervical cancer is indicative for a less effective immune response

    Article • Human Pathology, September 1996, Elsevier

    Professor Pancras C.W. Hogendoorn

  464. Dynamic contrast-enhanced MR imaging of musculoskeletal tumors: Basic principles and clinical applications

    Article • Journal of Magnetic Resonance Imaging, March 1996, Wiley

    Professor Pancras C.W. Hogendoorn

  465. Can conventional radiographs be used to monitor the effect of neoadjuvant chemotherapy in patients with osteogenic sarcoma?

    Article • Skeletal Radiology, January 1996, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  466. Calcified meningioma of the skull base simulating chondrosarcoma

    Article • European Journal of Radiology, December 1995, Elsevier

    Professor Pancras C.W. Hogendoorn

  467. Lymph node staging standards in gastric cancer.

    Article • Journal of Clinical Oncology, September 1995, American Society of Clinical Oncology (ASCO)

    Professor Pancras C.W. Hogendoorn

  468. Osteosarcoma and Ewing's sarcoma after neoadjuvant chemotherapy: value of dynamic MR imaging in detecting viable tumor before surgery.

    Article • American Journal of Roentgenology, September 1995, American Roentgen Ray Society

    Professor Pancras C.W. Hogendoorn

  469. Translocation Identification of an Ews-Pseudogene Using Detection by RT-PCR in Ewings-Sarcoma

    Article • Biochemical and Biophysical Research Communications, August 1995, Elsevier

    Professor Pancras C.W. Hogendoorn

  470. Keratin immunoreactivity in melanoma of soft parts (clear cell sarcoma)

    Article • Histopathology, July 1995, Wiley

    Professor Pancras C.W. Hogendoorn

  471. Treatment of high-grade bone sarcomas with neoadjuvant chemotherapy: the utility of sequential color Doppler sonography in predicting histopathologic response.

    Article • American Journal of Roentgenology, July 1995, American Roentgen Ray Society

    Professor Pancras C.W. Hogendoorn

  472. Can MRI predict the histopathological response in patients with osteosarcoma after the first cycle of chemotherapy?

    Article • Clinical Radiology, June 1995, Elsevier

    Professor Pancras C.W. Hogendoorn

  473. Glomerulopathy induced by a single monoclonal autoantibody against GP330

    Article • Nephrology Dialysis Transplantation, April 1995, Oxford University Press (OUP)

    Professor Pancras C.W. Hogendoorn

  474. Immunostaining of chain-specific keratins on formalin-fixed, paraffin-embedded tissues: a comparison of various antigen retrieval systems using microwave heating and proteolytic pre-treatments.

    Article • Journal of Histochemistry & Cytochemistry, April 1995, SAGE Publications

    Professor Pancras C.W. Hogendoorn

  475. Classification of histopathologic changes following chemotherapy in Ewing's sarcoma of bone

    Article • Skeletal Radiology, October 1994, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  476. Monitoring the effect of chemotherapy in Ewing's sarcoma of bone with MR imaging

    Article • Skeletal Radiology, October 1994, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  477. Adamantinoma of the long bones. A clinicopathological study of thirty-two patients with emphasis on histological subtype, precursor lesion, and biological behavior.

    Article • Journal of Bone and Joint Surgery, October 1994, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  478. Changes in tumor perfusion induced by chemotherapy in bone sarcomas: color Doppler flow imaging compared with contrast-enhanced MR imaging and three-phase bone scintigraphy.

    Article • Radiology, May 1994, Radiological Society of North America (RSNA)

    Professor Pancras C.W. Hogendoorn

  479. Metastasis of Breast Carcinoma to a Primary Mucinous Cystadenocarcinoma of the Ovary

    Article • Gynecologic Oncology, January 1994, Elsevier

    Professor Pancras C.W. Hogendoorn

  480. Adamantinoma of the Long Bones: Keratin Subclass Immunoreactivity Pattern with Reference to Its Histogenesis

    Article • The American Journal of Surgical Pathology, December 1993, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  481. Reply

    Article • Radiology, November 1993, Radiological Society of North America (RSNA)

    Professor Pancras C.W. Hogendoorn

  482. Diagnosis of low-grade chondrosarcoma.

    Article • Radiology, November 1993, Radiological Society of North America (RSNA)

    Professor Pancras C.W. Hogendoorn

  483. Cartilaginous tumors: correlation of gadolinium-enhanced MR imaging and histopathologic findings.

    Article • Radiology, March 1993, Radiological Society of North America (RSNA)

    Professor Pancras C.W. Hogendoorn

  484. Antigen size influences the type of glomerular pathology in chronic serum sickness

    Article • Nephrology Dialysis Transplantation, January 1993, Oxford University Press (OUP)

    Professor Pancras C.W. Hogendoorn

  485. Endothelial Activation Antigens in Pulmonary Leukostasis in Leukemia

    Article • Acta Haematologica, January 1993, Karger Publishers

    Professor Pancras C.W. Hogendoorn

  486. Unusual Manifestations of Yersinia enterocolitica Infections Diagnosed Using Novel Methods

    Article • Clinical Infectious Diseases, October 1992, Oxford University Press (OUP)

    Professor Pancras C.W. Hogendoorn

  487. Differential renal uptake of 201T1

    Article • Nuclear Medicine Communications, October 1991, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  488. Renal Uptake of TI-201 in Hypertensive Patients Undergoing Myocardial Perfusion Imaging

    Article • Clinical Nuclear Medicine, February 1990, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  489. Development of Progressive Glomerulosclerosis in Experimental Chronic Serum Sickness

    Article • Nephrology Dialysis Transplantation, January 1990, Oxford University Press (OUP)

    Professor Pancras C.W. Hogendoorn

  490. Pathogenesis of experimental lupus nephritis: a role foranti-basement membrane and anti-tubular brush border antibodiesin murine chronic graft-versus-hostdisease

    Article • Clinical & Experimental Immunology, January 1990, Oxford University Press (OUP)

    Professor Pancras C.W. Hogendoorn

  491. Myxoid tumours of soft tissue

    Article • Pathology, January 1980, Elsevier

    Professor Pancras C.W. Hogendoorn

  492. Segmentation of bone tumor in MR perfusion images using neural networks and multiscale pharmacokinetic features

    Article • Institute of Electrical & Electronics Engineers (IEEE)

    Prof Alejandro F Frangi, Professor Pancras C.W. Hogendoorn

  493. Pitfalls in pathology of soft tissue sarcomas

    Article • Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn